Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Everolimus are two different dosage forms. Select the recommended dosage form based on the indication. Do not combine Everolimus to achieve the total dose. Modify the dosage for patients with hepatic impairment or for patients taking drugs that inhibit or induce P glycoprotein (P-gp) and CYP3A4.Hormone Receptor-Positive, HER2-Negative Breast Cancer: The recommended dosage of Everolimus is 10 mg orally once daily until disease progression or unacceptable toxicity.Neuroendocrine Tumors (NET): The recommended dosage of Everolimus is 10 mg orally once daily until disease progression or unacceptable toxicity.Renal Cell Carcinoma (RCC): The recommended dosage of Everolimus is 10 mg orally once daily until disease progression or unacceptable toxicity.Tuberous Sclerosis Complex (TSC): Associated Renal Angiomyolipoma: The recommended dosage of Everolimus is 10 mg orally once daily until disease progression or unacceptable toxicity.Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA): The recommended starting dosage of Everolimus is 4.5 mg/m2 orally once daily until disease progression or unacceptable toxicity.Tuberous Sclerosis Complex (TSC)-Associated Partial-Onset Seizures: The recommended starting dosage of Everolimus is 5 mg/m2 orally once daily until disease progression or unacceptable toxicity.
Side Effects
Most common side effects (occurring in 30% or more of patients) differ by the condition being treated. For breast cancer, neuroendocrine tumours (NET), and renal cell carcinoma (RCC), these include mouth sores, infections, rash, tiredness, diarrhoea, fluid retention (swelling), abdominal pain, nausea, fever, weakness, cough, headache, and reduced appetite. For TSC-associated renal angiomyolipoma, the most common side effect is mouth sores. For TSC-associated SEGA (a type of brain tumour), the most common side effects are mouth sores and respiratory tract infection. For TSC-associated partial-onset seizures, the most common side effect is mouth sores.
Cautions & Contraindications
Warnings & Precautions
Non-Infectious Pneumonitis: Monitor for clinical symptoms or radiological changes. Withhold or permanently discontinue based on severity.Infections: Monitor for signs and symptoms of infection. Withhold or permanently discontinue based on severity.Severe Hypersensitivity Reactions: Permanently discontinue for clinically significant hypersensitivity.Angioedema: Patients taking concomitant angiotensin-converting-enzyme (ACE) inhibitors may be at increased risk for angioedema. Permanently discontinue for angioedema.Stomatitis: Initiate dexamethasone alcohol-free mouthwash when starting treatment.Renal Failure: Monitor renal function prior to treatment and periodically thereafter.Risk of Impaired Wound Healing: Withhold for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of treatment after resolution of wound healing complications has not been established.Geriatric Patients: Monitor and adjust dose for adverse reactions.Metabolic Disorders: Monitor serum glucose and lipids prior to treatment and periodically thereafter. Withhold or permanently discontinue based on severity.Myelosuppression: Monitor hematologic parameters prior to treatment and periodically thereafter. Withhold or permanently discontinue based on severity.Risk of Infection or Reduced Immune Response with Vaccination: Avoid live vaccines and close contact with those who have received live vaccines. Complete recommended childhood vaccinations prior to starting treatment.Radiation Sensitization and Radiation Recall: Severe radiation reactions may occur.Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of reproductive potential of the potential risk to a fetus and to use effective contraception.
Contraindications
Clinically significant hypersensitivity to everolimus or to other rapamycin derivatives.